局部晚期非小细胞肺癌根治性放化疗后原发肿瘤失败:NRG LU-008 意义简报
单中心回顾 2011–2021 年 786 例接受根治性放化疗的局部晚期非小细胞肺癌患者,分析首次失败模式并回顾性评估 LU-008 入组资格。孤立性原发肿瘤失败 5 年累积发生率 10%,含原发肿瘤失败的局部区域失败中仅 41% 符合 LU-008 标准,中央型肿瘤是主要排除原因且原发失败更早。
要点
- 远处失败最常见,但局部区域失败仍占 42%,原发肿瘤失败需关注。
- 含原发肿瘤失败的局部区域失败仅 41% 符合 LU-008 标准。
- 中央型原发被 LU-008 排除且原发失败更早(中位 12.1 vs 22.4 月)。
核心结论
- 远处失败虽为最常见失败部位,局部区域失败仍是问题。
- 放化疗后许多原发肿瘤失败发生于会被 LU-008 排除的患者,主要因中央型肿瘤位置。
- 中央型原发高危亚组可能需要 LU-008 范式之外的替代增量或联合模式策略。
研究设计与样本
- 单中心回顾性研究,纳入 2011 至 2021 年连续接受根治性放化疗(>60 Gy,1.8–2 Gy/次,±免疫治疗)的成人患者。
- 共 786 例患者,中位随访 66.9 个月。
- 首次进展分为孤立局部区域失败、孤立远处失败或同步局部区域失败+远处失败,局部区域失败再分为原发肿瘤失败、区域失败或两者兼有。
- 原发肿瘤失败定义为原发肿瘤大体肿瘤体积 90% 等剂量线内的影像学失败。
- 回顾性应用 LU-008 入组标准(肿瘤 <7 cm、≥1 个淋巴结、原发灶距淋巴结临床肿瘤体积 >2 cm),采用 Fine-Gray 模型以死亡为竞争风险计算累积发生率。
主要发现
- 共发生 484 次首次失败:孤立局部区域失败 109 例、同步局部区域失败+远处失败 122 例、孤立远处失败 253 例。
- 孤立原发肿瘤失败 40 例(5.1%),原发肿瘤失败+区域失败 29 例(3.7%)。
- 5 年累积发生率:任何远处失败 52%,任何局部区域失败 42%,任何孤立局部区域失败(无远处失败)25%,任何原发肿瘤失败(原发肿瘤失败+区域失败,无远处失败)17%,孤立原发肿瘤失败 10%。
- 含原发肿瘤失败的局部区域失败 69 例中仅 28 例(41%)符合 LU-008 标准。
- 接受免疫巩固治疗的患者失败模式相似。
关键数值与推荐
- LU-008 入组标准:肿瘤 <7 cm、≥1 个淋巴结、原发灶距淋巴结临床肿瘤体积 >2 cm。
- 原发肿瘤失败定义为原发肿瘤大体肿瘤体积 90% 等剂量线内的影像学失败。
- 5 年累积发生率:任何远处失败 52%、任何局部区域失败 42%、孤立原发肿瘤失败 10%。
- 含原发肿瘤失败的局部区域失败中符合 LU-008 标准比例为 41%(28/69)。
- 任何局部区域失败中 LU-008 不合格比例为 56%(129/231);不合格者原发肿瘤失败中位时间 12.1 个月 vs 合格者 22.4 个月(P = .002)。
临床怎么用
- 评估局部晚期非小细胞肺癌根治性放化疗后失败模式时,应关注原发肿瘤失败而非仅远处失败。
- 对中央型或超中央型原发肿瘤患者,需认识到其常不符合 LU-008 标准且原发失败更早,应考虑替代增量或联合模式策略。
- LU-008 的立体定向体部放疗增量范式可能不覆盖相当比例的原发肿瘤失败高危患者。
局限性
- 单中心回顾性研究,LU-008 资格为回顾性应用。
- 原发肿瘤失败基于影像学定义,可能存在评估偏倚。
- 未报告 LU-008 范式外替代策略的具体疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Locoregional failure (LRF) after definitive chemoradiation for locally advanced non-small cell cancer is suboptimal. LU-008 aims to improve local control through an stereotactic body radiation therapy boost. We quantified first-failure patterns after modern chemoradiation and determined whether patients with LRF had LU-008 eligibility. METHODS AND MATERIALS: Consecutive adults treated with definitive chemoradiation (>60 Gy, 1.8-2 Gy/fraction ± immunotherapy) from 2011 to 2021 at a single institution were reviewed. First progression was classified as isolated LRF, isolated distant failure (DF), or synchronous LRF + DF; LRF was subclassified as primary tumor failure (PTF), regional failure (RF), or PTF + RF. PTF was defined radiographically within the 90% isodose of the primary tumor gross tumor volume. LU-008 eligibility (tumor <7 cm, ≥1 node, primary >2 cm from nodal clinical tumor volume) was applied retrospectively. Cumulative incidence functions used Fine-Gray models with death as a competing risk. RESULTS: Among 786 patients (median follow-up 66.9 months), 484 first failures occurred: 109 isolated LRF, 122 synchronous LRF + DF, and 253 isolated DF. Isolated PTF occurred in 40 patients (5.1%); PTF + RF in 29 (3.7%). Five-year cumulative incidence was 52% for any DF, 42% for any LRF, 25% for any isolated LRF (DF-free), 17% for any PTF (PTF + RF, DF-free), and 10% for isolated PTF. Only 28 of 69 PTF-containing LRFs (41%) met LU-008 criteria. Failure patterns were similar for patients who received immunotherapy consolidation. Overall, 129 of 231 patients with any LRF (56%) were LU-008-ineligible, commonly due to central or ultracentral primaries, and experienced earlier PTF (median, 12.1 vs 22.4 months; P = .002). PTF risk increased steeply with primary tumor gross tumor volume up to ∼200 cm2. CONCLUSIONS: Although DF is the most common site of failure, LRF remains a problem. Many PTFs after chemoradiation occur in patients who would be excluded from LU-008, mainly because of central-tumor location. This high-risk subset of central primaries may require alternative escalation or combined modality strategies beyond the proposed LU-008 paradigm.
引用
- Friedes C, Yegya-Raman N, Iocolano M, et al. Primary Tumor Failure After Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Brief Report on the Implications for NRG LU-008. Int J Radiat Oncol Biol Phys. 2025. PMID: 40967373. doi:10.1016/j.ijrobp.2025.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。